Company Overview - Enovis operates as a global medical technology company focused on musculoskeletal health, leveraging a broad product portfolio and established distribution channels to serve healthcare professionals and institutions [5] - The company generates revenue through the sale of proprietary medical devices and solutions, targeting orthopedic specialists, surgeons, physical therapists, and other healthcare providers [7] Recent Developments - On February 18, 2026, Front Street Capital Management, Inc. reported an increase in its position in Enovis by 156,069 shares, valued at approximately $4.61 million [2] - The quarter-end value of Enovis's position rose by $3.40 million, reflecting both the additional shares and share price changes [2] - Enovis shares were priced at $25.42, down 36.5% over the past year, significantly underperforming the S&P 500's roughly 16% gain [6] Financial Performance - Enovis reported full-year revenue of $2.2 billion, representing a 7% increase, with organic growth of 6% [8] - Reconstructive sales climbed by 10%, and adjusted EBITDA reached $403 million [8] - Fourth quarter sales hit $576 million, with adjusted earnings per share of $0.95, exceeding expectations [8] Market Position and Strategy - The recent transaction by Front Street Capital Management indicates a measured turnaround strategy, with Enovis's allocation in the fund representing 1.37% of its 13F assets under management as of December 31, 2025 [6] - The company is guiding for revenue of up to $2.37 billion in 2026, with expectations of higher EBITDA [8][10]

Company Overview - Enovis Corporation is a global medical technology company specializing in orthopedic solutions for musculoskeletal conditions, leveraging a diversified product portfolio and established distribution channels to meet the needs of healthcare professionals and patients [8] - The company develops and distributes orthopedic medical devices, including bracing, therapy products, bone growth stimulators, and reconstructive joint implants, targeting both healthcare professionals and retail channels under the DJO brand [7] Financial Performance - As of November 25, 2025, Enovis Corporation's share price was $30.32, with a market capitalization of $1.68 billion and a trailing twelve months (TTM) revenue of $2.23 billion [4] - The company's share price has decreased by 40.48% over the past year, with shares down approximately 38.6% due to expanding quarterly net losses, which increased from $37 million in the second quarter to $571 million in the third quarter [4][9] - The third quarter's expanded net loss included a non-cash goodwill impairment charge of $548 million, which is not expected to recur, while sales in the Recon segment grew by 12% year over year and P&R sales grew by 6% year over year [10] Insider Activity - John Kleckner, the Principal Accounting Officer, purchased 2,468 shares on November 25, 2025, marking the largest single-day acquisition on record for him, increasing his direct ownership by 25.1% from 9,834 to 12,302 shares [2][6] - The transaction value was $74,829.76, with shares acquired at $30.32 each, although the share price had declined to $29.36 by December 1, 2025, representing a drop of 3.2% from the purchase price [2][6]